How to Get Mounjaro Online in 2026
Mounjaro (tirzepatide 2.5–15 mg weekly) is FDA-approved for type 2 diabetes, the same molecule as Zepbound, which carries the obesity indication. Mounjaro vs Zepbound is purely an indication and labeling distinction; pharmacies cannot freely substitute. Telehealth platforms prescribe Mounjaro for on-label diabetic use; for weight loss they direct patients to Zepbound. Cash-pay retail runs $1,000–$1,200/mo; the Lilly savings card can drop commercial copays to ~$25/mo.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
Mounjaro is a once-weekly subcutaneous tirzepatide injection (2.5, 5, 7.5, 10, 12.5, 15 mg) FDA-approved May 2022 for adults with type 2 diabetes. Mechanism: dual GIP and GLP-1 receptor agonist, the only dual incretin currently on the market. Available in pen and KwikPen formats. Pharmacologically identical to Zepbound; legally and commercially separate SKUs.
Adults with type 2 diabetes seeking glycemic control beyond metformin or after failing on a single GLP-1, particularly those who want the strongest weight-loss-as-side-effect profile (mean -7 to -12% body weight in SURPASS trials). Strong fit for patients with both T2D and obesity who don't qualify for Zepbound through their insurance. Same MTC/MEN-2 contraindications as Zepbound.
Standard titration: 2.5 mg (weeks 1–4) → 5 mg (weeks 5–8) → escalating every 4 weeks if tolerated up to 15 mg. KwikPen and pen formats. Cash-pay $1,000–$1,200/mo without insurance. Lilly savings card drops commercial copays to ~$25/mo for covered patients. Side-effect profile per SURPASS-2: nausea (22%), diarrhoea (16%), decreased appetite (10%), constipation (10%). Lower side-effect rates than Zepbound 15 mg because diabetic patients typically titrate slower and many stay at 5–10 mg.
Verified Offers for Mounjaro
What the Studies Actually Show
Mounjaro is FDA-approved tirzepatide for type 2 diabetes. The evidence below comes from the SURPASS program (registration trials), the SURMOUNT obesity program (relevant to expected weight effects in patients with T2D), and the FDA prescribing information.
| Endpoint | Finding |
|---|---|
| Mean weight loss (SURMOUNT-1, 72 weeks, 15 mg)1 | −20.9% body weight vs −3.1% placebo in adults with obesity without diabetes |
| Mean weight loss with T2D (SURMOUNT-2, 72 weeks, 15 mg)2 | −14.7% body weight in adults with type 2 diabetes |
| Sleep apnea (SURMOUNT-OSA)3 | Tirzepatide reduced apnea-hypopnea index (AHI) by ~25–29 events/hour vs placebo at 52 weeks; FDA-approved labeling for moderate-to-severe OSA in obesity |
| GI side effects (FDA prescribing information)4 | Nausea ≥10%, diarrhea ≥10%, vomiting ≥5%, constipation ≥5% |
| Boxed warning4 | Risk of thyroid C-cell tumors observed in rodent studies; contraindicated in personal/family history of MTC or MEN 2 |
| A1C reduction (T2D, SURPASS program)5 | ≈1.9–2.4% A1C reduction at 15 mg weekly across SURPASS-1 through SURPASS-5 |
| Compounded tirzepatide — evidence basis6 | Active ingredient is identical to Zepbound/Mounjaro; efficacy is inferred from the active ingredient. FDA does not formally approve compounded products |
Frequently Asked Questions
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SURMOUNT-2 — Lancet 2023 · Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613–626.
- SURMOUNT-OSA — NEJM 2024 · Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193–1205.
- FDA Prescribing Information — Zepbound (tirzepatide) · ZEPBOUND (tirzepatide) injection, for subcutaneous use. U.S. Food and Drug Administration prescribing information.
- SURPASS — program summary · Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.
- FDA — Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (last updated 2024).
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.